PDF

The cosmetics industry has always operated under compliance requirements, but 2025 presents an era of unprecedented pressure.

In late 2024, the Financial Times reported that 6% of inspected cosmetic products in the EU contained prohibited substances, including PFAS, raising serious health and environmental concerns. At the same time, consumer expectations are shifting—younger buyers are demanding more transparency than ever, forcing brands to rethink how they communicate ingredient safety and regulatory adherence.

And it’s not just consumer scrutiny that’s intensifying. The industry is still grappling with MoCRA, and as of January, the FDA reported 135,000 imported cosmetic products as non-compliant. REACH revisions are on the horizon, while regulatory divergence between the UK and EU is accelerating, creating compliance headaches for brands operating across markets. On top of that, the growing adoption of AI in personal care is bringing cosmetics into the scope of the EU AI Act, introducing new challenges that few are prepared for.

The Cosmetics Compliance Forum is where the industry comes together to face these challenges head-on. Over two days, we provide a platform for beauty innovators and regulatory experts to share insights, solutions, and strategies for staying compliant without compromising innovation. Covering everything from sustainability practices and ingredient trends to regulatory-driven business impacts and AI’s role in compliance, the Forum delivers critical knowledge through two expert-led content tracks designed for both regulatory affairs professionals and product developers.

If you’re navigating compliance complexities or looking to future-proof your business, this is the event you can’t afford to miss. Join us from September 9th to 11th and be part of the conversation that will shape the future of cosmetics.

The advent of Artificial Intelligence (AI) has initiated a transformative wave across various industries, with the pharmaceutical sector standing at the forefront of this technological revolution. In the pharmaceutical industry, AI is not just a tool but a catalyst reshaping drug discovery, clinical trials, supply chain, and manufacturing. Understanding the impact, implementation challenges, and future potential of these evolving technologies is essential for industry stakeholders.

AI has massive potential across the entire pharmaceutical value chain and the broader healthcare industry. This report will drill down into some of the most exciting opportunities within the pharmaceutical value chain, including drug discovery and development, clinical trials, manufacturing, and supply chain management—key segments where AI is driving significant advancements.

Dive into an exclusive preview of the content below and enter details to receive the full copy

Introduction:

The advent of Artificial Intelligence (AI) has initiated a transformative wave across various industries, with the pharmaceutical sector standing at the forefront of this technological revolution. In the pharmaceutical industry, AI is not just a tool but a catalyst reshaping drug discovery, clinical trials, supply chain, and manufacturing. Understanding the impact, implementation challenges, and future potential of these evolving technologies is essential for industry stakeholders.

AI has massive potential across the entire pharmaceutical value chain and the broader healthcare industry. This report will drill down into some of the most exciting opportunities within the pharmaceutical value chain, including drug discovery and development, clinical trials, manufacturing, and supply chain management—key segments where AI is driving significant advancements

Learn how AI enhances target identification, lead optimization, data integration, predictive analytics, and automation. Discover case studies from BenevolentAI, AstraZeneca, and more. Connect with industry leaders and innovators. Enhance your R&D processes and maximize ROI with cutting-edge AI applications.

The EU AI Act is a comprehensive regulation designed to ensure AI systems are safe, transparent, and respectful of fundamental rights. It categorises AI systems based on their risk levels—ranging from minimal risk to high risk—and establishes specific requirements for each category. For the pharmaceutical and healthcare industries, this means greater scrutiny, enhanced data quality, robust compliance frameworks, and significant operational adjustments. As the industry increasingly relies on AI for drug discovery, clinical trials, and patient care, understanding and adapting to the EU AI Act is crucial for compliance and innovation. This guide to the EU AI Act will ensure that you understand how to prepare for its full implementation while remaining at the forefront of innovation.

Dive into an exclusive preview of the content below and enter details to receive full copy

Introduction:

The EU AI Act represents a significant regulatory development aimed at harmonising rules for Artificial Intelligence (AI) within the European Union. This legislation is designed to address the risks associated with AI, ensuring its safe and ethical deployment. For the pharmaceutical and healthcare sectors, understanding the implications of the AI Act is crucial, given the industry’s increasing reliance on AI for drug discovery, clinical trials, and patient care.

What is the EU AI Act?

The EU AI Act is a comprehensive regulation designed to ensure AI systems are safe, transparent, and respectful of fundamental rights. It categorises AI systems based on their risk levels—ranging from minimal risk to high risk—and establishes specific requirements for each category.

High-risk AI systems, such as those used in healthcare, must comply with stringent standards to mitigate potential harms and biases. AI systems that present unacceptable risks, such as real-time biometric identification in public spaces, are banned outright (DW, 2024) (Reed Smith LLP, 2024).

To read more, including an implementation timeline, enter your details below. 

Discover how Artificial Intelligence (AI) is revolutionising pharmaceutical supply chains, enhancing operational efficiencies from raw material sourcing to final product delivery. This infographic delves into the key areas where AI is making a significant impact, including demand forecasting, regulatory compliance, and risk management. Download to explore real-world applications and the actionable steps companies can take to seamlessly integrate AI.

Artificial Intelligence (AI) is transforming the landscape of clinical trials, significantly enhancing patient recruitment and retention processes. This article explores how AI is being utilised to improve these critical aspects of clinical trials, ensuring more efficient, cost-effective, and successful outcomes.

The rapid advancement of AI technology offers unprecedented opportunities for the pharmaceutical industry, where drug discovery moves at unprecedented speeds, clinical trials are streamlined for efficiency, and regulatory approvals are faster than ever before. However, sceptical of the "AI hype" pharma leaders need a clear path to AI integration.

This September, Pharma IQ is bringing together key AI stakeholders from big pharma responsible for drug discovery, clinical trials and supply chain to meet with key technology consultancies and vendors who will share practical applications and case studies.

Amongst the sea of AI events, AI for Pharma & Healthcare is uniquely positioned, there will be 3 streams consisting of drug discovery, clinical trials and supply chain to ensure that sponsors can showcase their expertise to a targeted audience from our three streams. The sponsorship prospectus has more information on the audience, key audience drivers and sponsorship package opportunities.